Energesis Pharmaceuticals
The Leader in Harnessing Brown Fat to Fight Obesity & Diabetes
- Stage Prototype Ready
- Industry Biotechnology
- Location Cambridge, MA, USA
- Currency USD
- Founded July 2010
- Employees 4
- Incorporation Type C-corp
- Website energesispharma.com
Company Summary
Energesis Pharmaceuticals is developing a new class of highly differentiated drugs that turn the body into a calorie burning machine, addressing critical unmet needs in the rapidly growing obesity market. By leveraging brown fat, a normal mammalian system, our therapeutic candidates produce highly significant weight loss, without affecting muscle mass or appetite, and critically, synergize with drugs of the GLP-1 class.
Team
-
CEO & Co-founderDr. Freeman formerly co-founded Zafgen, which developed a novel anti-obesity approach and went public in 2015. Previously he was a Venture Partner with GreatPoint Ventures and an Engagement Manager at MEDACorp (now Leerink Swann Strategic Advisors). Dr. Freeman completed his clinical training at the University of Pennsylvania, his medical degree at Washington University in St. Louis, and his undergraduate studies at MIT.
-
CSO & Co-founderDr. Boss is a recognized expert in energy metabolism who has made seminal contributions to the field and previously held positions at Novartis, Adipogenix, and Sirtris. He discovered 2 of the 3 known UnCoupling Proteins (UCPs), which are critical for brown fat function, as well as the human brown fat stem cells at the core of our proprietary discovery system. He has published 50+ scientific papers in endocrinology and energy metabolism.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.